This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Dextromethorphan: Difference between revisions
>Artoria2e5 edit comment |
>Artoria2e5 m →Dextromethorphan/Bupropion: oop |
||
| Line 57: | Line 57: | ||
</blockquote> | </blockquote> | ||
So [[User:JH556|JH556]], I ''guess'' the relative safety has something to do with it being extended-release. I don't know how much safety margin | So [[User:JH556|JH556]], I ''guess'' the relative safety has something to do with it being extended-release. I don't know how much safety margin goes into the "space doses at least 8hrs apart" disclaimer, but it has to be... decent enough? | ||
The existing source https://sci-hub.se/10.1097/01.jcp.0000162805.46453.e3 speculates at a risk, but it (and the deleted line about Bupropion) does not go into the psychoactive consequences of having less DXM convert to dextrorphan. This should produce a very significant change in the subjective effect, as dextrorphan is much more potent at the hallucinogenic NMDAR than DXM. | The existing source https://sci-hub.se/10.1097/01.jcp.0000162805.46453.e3 speculates at a risk, but it (and the deleted line about Bupropion) does not go into the psychoactive consequences of having less DXM convert to dextrorphan. This should produce a very significant change in the subjective effect, as dextrorphan is much more potent at the hallucinogenic NMDAR than DXM. | ||